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Abstract
Background: The use of human saphenous vein grafts (HSVGs) as a bypass conduit
is a standard procedure in the treatment of coronary artery disease while their early
occlusion remains a major problem.
Methods: We have developed an ex vivo perfusion system, which uses standardized
and strictly controlled hemodynamic parameters for the pulsatile and non-static
perfusion of HSVGs to guarantee a reliable analysis of molecular parameters under
different pressure conditions. Cell viability of HSVGs (n = 12) was determined by the
metabolic conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
(MTT) into a purple formazan dye.
Results: Under physiological flow rates (10 mmHg) HSVGs remained viable for two
weeks. Their exposure to arterial conditions (100 mmHg) was possible for one week
without important reduction in viability. Baseline expression of matrix
metalloproteinase-2 (MMP-2) after venous perfusion (2.2 ± 0.5, n = 5) was strongly
up-regulated after exposure to arterial conditions for three days (19.8 ± 4.3) or five
days (23.9 ± 6.1, p < 0.05). Zymographic analyses confirmed this increase on the
protein level. Our results suggest that expression and activity of MMP-2 are strongly
increased after exposure of HSVGs to arterial hemodynamic conditions compared to
physiological conditions.
Conclusion: Therefore, our system might be helpful to more precisely understand
the molecular mechanisms leading to an early failure of HSVGs.
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Background
Coronary artery bypass grafting (CABG) using venous grafts is a standard procedure in
the treatment of advanced coronary artery disease. However, vein graft occlusion
implanted in an arterial pressure environment is still a major problem [1]. Approxi-
mately 15 to 20% of human saphenous vein grafts (HSVGs) occlude within one month
and 25% within the first year. Ten years after CABG about 50% of the HSVGs are
occluded and 25% have been severely stenosed [2-6]. Early changes in vein grafts
include endothelial disruption leaving the graft vulnerable to thrombotic incidents and
smooth muscle cell (SMC) migration and proliferation from the media into the intima
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reproduction in any medium, provided the original work is properly cited.within the first week after grafting [1,7]. The vein graft intimal thickening and
remodeling occurs as an adaptation to increased wall stress and arterial flow with up
to 15% of graft stenosis during the first year [8]. Under physiological conditions
human saphenous veins are exposed to low pressure conditions (~5-10 mmHg), a non-
pulsatile flow and a shear stress of 1-6 dyne/cm
2 [9]. After grafting and implantation
into the coronary artery system the graft must support higher pressure conditions
(~60-140 mmHg), a pulsatile flow and a shear stress range of 10-70 dyne/cm
2 during
the cardiac cycle [9,10]. Beyond the first year after bypass surgery the development of
graft atheroma and accordingly atherosclerotic vein graft stenosis is the dominant pro-
cess underlying the failure of HSVGs [1,11]. Formation and evolution of atherosclerotic
plaques are associated with variations in matrix metalloproteinase (MMP) expression.
The gelatinases play a central role in matrix degeneration and SMC migration, a pro-
cess which substantially contributes to vein graft failure. The involvement of different
MMPs in vascular remodeling has been shown [12-14] whereas little is known about
the specific role of gelatinases in HSVGs. While MMP-2 is either absent or only pre-
sent at low levels in normal veins, its expression becomes elevated after graft implanta-
tion which may be a response to injuries during graft preparation or the exposure to
the arterial environment [8]. It is generally accepted that the arterial mechanical envir-
onment plays a role in vein graft failure, yet the specific mechanical conditions and
biological mechanisms have not been completely understood. Vessels cultured under
static conditions have been widely used to study effects of pre-existing intimal hyper-
plasia (IH) [15]. Berceli et al. used a rabbit model to analyze intimal changes and
MMP gene and protein expression after bilateral common carotid interposition vein
grafting with defined regions of different wall shear [16]. The group of Patterson has
used HSVGs in organ culture under static conditions or perfusion for seven days with
the restriction of shear force calculation and the differentiation just between low-flow
and high-flow conditions [17]. Compared to the animal model of Berceli et al. the ex
vivo perfusion system of Patterson et al. has a nonpulsatile hemodynamic environment,
no blood-surface interaction and potential problems with delivery of nutrition or gas.
Gusic and colleagues investigated the role of the mechanical environment in vein
remodeling in a higher developed ex vivo perfusion system with a main focus on med-
ial and intimal growth in the perfused veins. They ran their perfusions system with five
different ex vivo hemodynamic environments and showed that pressure and shear
stress act independently to regulate vein remodeling [7]. Yet, their study had the lim-
itation of unstable pressure profiles during the course of the experiment. In the present
study we have developed an ex vivo perfusion system which can be used to perfuse
HSVGs with tightly controlled, steady and standardized perfusion profiles. We have
defined the viability time course of perfused HSVGs exposed to arterial and venous
perfusion profiles. In addition, we provide evidence that our system is suitable to
detect alterations of molecular markers such as MMP-2 as a consequence of prepara-
tive injury or increased arterial perfusion pressure.
Methods
Tissue Preparation
Nonvaricose HSVGs were obtained from 35 patients (mean age 71.4 ± 7.7 years; nine
females, 26 males) undergoing CABG surgery in the German Heart Center Munich.
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perature until implant. One part of the graft was immediately stored in Ringer solution
on ice and transferred from the operating room to the laboratory. One small piece was
directly snap-frozen in liquid nitrogen and stored at -80°C until further use as unper-
fused control tissue. This piece served as a reference to determine relative gene expres-
sion. The other part of the vein was mounted into the perfusion device as described.
The procedure was acknowledged by the local ethical committee (Ethikkommission
der TU München, Project no. 1588/06).
Ex vivo perfusion system
The circuit of the perfusion system is driven by a roller pump ISMATEC S2
(Wertheim, Germany) producing a pulsatile and non-static flow. All silicon tubings
and the vessel chamber are sterilized prior to use. The vessel mounting procedure is
carried out under a biological safety cabinet (NuAire, Plymouth, MN). Constant
pressure conditions are maintained using a syringe pump (MC Medizintechnik
GmbH, Alzenau, Germany). The entire system is placed into a styrofoam-isolated
chamber to maintain a constant temperature of 37°C. Disposable pressure sensors
(DPT-9300, Codan Critical Care, Forstinning, Germany) are placed on both sides of
the vessel chamber to permanently monitor and facilitate the control of pressure
conditions of the circuit. All functions and settings are controlled by a PC with a
program written in java. Pressure is controlled by a PID-algorithm, data are logged
continuously.
Perfusion of human saphenous vein grafts
HSVGs were fixed in the perfusion device by suture ligation (Ethibond Vicryl 3-0, Ethi-
con GmbH, Norderstedt, Germany) and adjusted to a length matching the in vivo con-
ditions. Total time from operating room to perfusion was less than one hour. The
perfusion medium was DMEM/Ham’s F-12 (PAA, Marburg, Germany) supplemented
with 10% FCS, 2 mM glutamine and antibiotics (100 U/ml penicillin and 100 μg/ml
streptomycin). Veins were perfused with venous conditions (flow: 5 ml/min, 10 mmHg,
n = 12) or with arterial conditions (flow: 50 ml/min, 100 mmHg, n = 12) for various
time periods. At the end of each experiment vein ends were discarded. The other part
of the vein was snap-frozen in liquid nitrogen and stored at -80°C until further use. In
long-term experiments the medium was replaced every two days. The pH of the med-
ium remained stable within this period.
Determination of viability of vein grafts and histology
To verify tissue viability, a staining with MTT (Sigma, Munich, Germany) was per-
formed. In the presence of metabolically active viable cells the yellow MTT is con-
verted into a water-insoluble purple formazan product due to reduction by
mitochondrial dehydrogenases and other cellular enzymes [18,19]. MTT was stored as
a stock solution (5 mg/ml in PBS) at -20°C. Short segments of veins (n = 12) were
incubated in MTT diluted in serum-free medium to 0.5 mg/ml for one hour at 37°C.
To analyze potential degenerative changes in perfused vessels, sections of formalin
fixed and paraffin-embedded samples were analyzed after a conventional hematoxylin/
eosin staining.
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Frozen tissue pieces were minced using a Precellys24 lysis and homogenization system
(Peqlab, Erlangen, Germany) and total RNA was extracted using Trifast according to
the manufacturer’s recommendation (Peqlab). All RNA preparations were digested
with DNase I prior to cDNA synthesis using Omniscript RT kit (Qiagen, Hilden, Ger-
many). One μl of cDNA was amplified on a LightCycler 1.5 thermo cycler (Roche
Diagnostics, Mannheim, Germany) using the QuantiTect SYBR Green Kit (Qiagen)
and BSA (0.5 mg/ml) in a final volume of 20 μl. All primers were used in a final con-
centration of 0.5 μM. The following primers were used: b-actin forward 5’ CCA ACC
GCG AGA AGA TGA 3’, b-actin reverse 5’ CCA GAG GCG TAC AGG GAT AG 3’,
MMP-2 forward 5’ TGC TGG AGA CAA ATT CTG GA 3’, MMP-2 reverse 5’ GAT
GGC ATT CCA GGC ATC 3’. They amplify fragments of 96 and 90 bp, respectively.
After an initial activation of Taq polymerase for 15 min at 95°C specific products were
amplified during 40 cycles using the following conditions: 15 sec at 94°C (denatura-
tion), 20 sec at 60°C (annealing) and 20 sec at 72°C (elongation). The relative expres-
sion levels of MMP-2 in individual samples were calculated in relation to the
expression of the b-actin housekeeping gene. To compare independent samples the
ratios of MMP-2/b-actin were calculated.
Zymography
MMP-2 protein activities were evaluated by a standard gelatine zymography. Briefly,
100 mg of frozen HSVG tissue were homogenized in ice cold zymogram buffer (150
mM NaCl, 1 μmZ n C l 2,1 . 5m MN a N 3,2 0m MC a C l 2, 0.01% Triton X-100, 10 mM
cacodylic acid, pH 5.0). Samples were centrifuged at 4°C for 10 min at 20.000 × g.
The supernatant containing proteins was removed and stored at -80°C until further
use. Ten μg of extracted protein were mixed with zymogram loading buffer
(62.5 mM Tris/HCl, pH 6.8, 25% glycerol, 4% SDS, 0.01% bromophenol blue) and
separated in 15% SDS-PAGE gels containing 1 mg/ml type A gelatine from porcine
skin (SIGMA-Aldrich, Taufkirchen, Germany). To renature proteins, gels were
washed two times in 2.5% Triton X-100 for 15 min at room temperature and subse-
quently incubated in developing buffer, pH 7.5 (200 mM NaCl, 50 mM Tris, 5 mM
CaCl2, 0.02% Brij-35) overnight at 37°C. Gels were stained with 0.5% Coomassie Blue
R250 in 40% methanol/10% acetic acid for 15 min and destained in 40% methanol/
10% acetic acid until clear bands of lytic activity appeared. The reaction was stopped
by transfer of gels in aqua bidest. Gelatinolytic activity was quantified using ImageJ
software (version 1.43 u, National Institute of Health). The pixel intensities of bands
within each gel were normalized against the respective control of unperfused venous
tissue.
Statistical analysis
For the analysis of gene expression levels and MMP-2 gelatinolytic activity the compar-
ison was made using the unpaired Student’s t-test. Differences in the vessel viability
were calculated using the Mann-Whitney U-Test. Differences were considered to be
significant at values of p < 0.05.
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Establishment of the ex vivo perfusion system
Twenty four veins from twenty three patients were used for the ex vivo perfusion
experiments to establish and proof the reliability of the system. The veins were fixed
on tapered conical metal adapters with circular striae to ensure a tight fit of the grafts
throughout the whole experiment (Figure 1A). All components used in the vessel
chamber are biocompatible (PEEK, 316 L) thereby avoiding any potential interactions
with the veins. The grafts were brought to their initial length using the adjustment
device. Deaeration was performed by using two three way stop cocks. An overview
showing the components of the perfusion system is given in Figure 1B. Under arterial
pulsatile (Figure 1C) and non-static flow conditions three veins were cultured for one
day, five veins for three days and four veins for five days. To establish the reliability of
t h es y s t e mw ep e r f u s e df i v eH S V G sf o ro n e ,t h r e ev e i n sf o rt h r e ea n df o u rv e i n sf o r
five days with low pressure conditions (10 mmHg, flow rate 5 ml/min) which mimics
the physiological venous pressure profile. Sensors on both side of the vessel chamber
permanently surveyed the pressure inside the circuit (Figure 1B). In case of a pressure
decrease a tiny volume of medium was injected into the circuit from an external med-
ium reservoir mounted in a syringe pump. With this setup we were able to maintain
the pressure constantly within a deviation of less than 2 mmHg during the whole
experiment. The perfusion conditions were controlled by a customized software pack-
age. By using a PID control algorithm to control the syringe pump a constant pressure
could be secured throughout the whole experiment. Pressure data were logged every
10 seconds and were analyzed after every trial.
Human saphenous veins support arterial perfusion conditions for one week
Under venous conditions all tested veins contained viable cells throughout the vessel
wall for up to 12 days indicated by a conversion of MTT into a purple formazan pro-
duct (data not shown). Thereafter, the viability dropped (Figure 2A). We then analyzed
to what extent the veins would support an elevated pressure which corresponds to the
arterial situation (100 mmHg, flow rate 50 ml/min). After one and four days of arterial
perfusion all veins were fully viable (Figure 2B) and showed an intensive purple stain-
ing. Even after seven days the cells clearly showed metabolic activity though to a
reduced degree (Figure 2B). Beyond one week the veins did not support these elevated
pressure conditions evidenced by the complete lack of MTT conversion (Figure 2B).
Thus, we have successfully established a standardized system, which allows the perfu-
sion of human veins with an arterial pressure profile for up to one week.
To further explore potential pathological changes in HSVGs upon perfusion, we
investigated tissue sections from veins after perfusion with venous or arterial pressure
profiles at different time points by a hematoxylin/eosin staining. As a reference, we
used an unperfused section of the same vein. Exposure to venous pressure for three
days did not change the histology and even after five days a minor thickening of the
intimal layer was evident (Additional File 1, Figure S1). After arterial perfusion for one
day also no major changes could be noticed. However, after three days the intimal
layer started to visibly thicken and after five days extensive hyperproliferative areas
were seen (Additional File 1, Figure S1).
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We next addressed the question whether the system is suitable to record alterations in
gene expression as a consequence of exposure to different pressure profiles. To that
end we analyzed MMP-2 as its expression is known to increase as a consequence of
hypertension and vein graft preparative injury [20-22]. We first determined MMP-2
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Figure 1 Ex vivo perfusion system. A) Vessel chamber. 1: ports for medium exchange, 2: glass tubing, 3:
rotating wheel for length adjustment of sliding unit, 4: sliding unit, 5: Luer connector to circuit, 6: tapered
adapter to fix veins, 7: vessel chamber, 8: sealing ring. B) Components of the perfusion system. C) Logged
pressure time profile.
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Page 6 of 14expression in human veins which were perfused with 10 mmHg for one day which
revealed a baseline ratio of MMP-2/b-actin of 2.2 ± 0.5 (n = 5) compared to unper-
fused control tissue (Figure 3). Extended perfusion of HSVGs for three days gave a
similar result (3.7 ± 0.6, n = 3) and perfusion for five days under venous conditions
showed a slightly increased gene expression of 5.0 ± 1.0 (n = 4) (Figure 3). No signifi-
cant difference could be observed between venous perfusion of HSVGs for one or
three days. Perfusion with 10 mmHg revealed statistical significance between five days
and one day (p < 0.05) (data not shown), probably due to the elongated exposure in
the ex vivo system. Perfusion of HSVGs with 100 mmHg for one day yielded an MMP-
2 gene expression ratio which was similar to the reference (2.4 ± 0.4; n = 3) (Figure 3).
However, MMP-2 gene expression was significantly up-regulated when HSVGs were
exposed to an arterial perfusion profile for three days (19.8 ± 4.3; n = 5). This value
increased further when arterial conditions were extended to five days (23.9 ± 6.1; n =
4) (p < 0.05; Figure 3). Thus, the elevation of MMP-2 gene expression starts rapidly
when HSVGs are exposed to arterial flow conditions and it is maintained at this high
level for at least five days. We then determined whether this change in RNA expres-
sion was also reflected on the protein level in a zymographic analysis. Under venous
pressure MMP-2 activity corresponding to a molecular weight of 72 kD was detected,
corresponding the activity of pro-MMP-2 (Figure 4A). Exposure to an arterial pressure
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Figure 2 Viability of human saphenous vein grafts under different pressure conditions. A) Veins
were perfused with either venous (10 mmHg) or arterial pressure profiles (100 mmHg). Viability of cells was
tested using the MTT conversion assay as described in Material and Methods. n = 6 for both conditions. B)
Representative MTT stainings of HSVGs at different time points.
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Page 7 of 14for one day yielded similar patterns (Figure 4A). However, when arterial pressure pro-
files were applied for three or five days gelatinolytic activities were strongly increased.
In particular, the 63 kD form of MMP-2 showed a heavily increased activity when
compared to unperfused control tissues (Figure 4A). Quantification of the gelatinolytic
activity confirmed our results of MMP-2 mRNA expression (Figure 4B). Gelatinase
activity did not increase significantly between venous (2.1 ± 0.4, n = 5) and arterial
(3.4 ± 1.4, n = 5) perfusion after one day. According to the results of mRNA expres-
sion extended perfusion with arterial pressure for three (4.5 ± 1.4, n = 5) or five days
(5.6 ± 0.9, n = 5) revealed significantly elevated MMP-2 gelatinolytic activity compared
to venous conditions (2.5 ± 0.6, n = 5 and 2.7 ± 0.4, n = 5, respectively).
Thus, our novel ex vivo perfusion system proved its ability to monitor alterations in
the expression of genes which are expected to increase their activity due to elevated
pressure conditions on the RNA and protein level.
Discussion
A major problem with HSVGs remains their occlusion after a certain time. Transposi-
tion of a vein segment and exposure to the arterial hemodynamic environment leads
to an acute increase in flow rates and intraluminal pressure and is thought to be a
potential trigger for the pathological remodeling of HSVGs [22,23]. Gene expression
profiling approaches revealed that many genes and multiple pathways are differentially
regulated under these conditions [24-26]. In the present study, we have established an
ex vivo perfusion system developed to mimic the arterialization of HSVGs. The culture
system provides the ability to reproduce the initial events taking place when the grafted
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Figure 3 Increase of MMP-2 expression in human saphenous vein grafts after exposure to arterial
pressure. HSVGs were perfused with venous (10 mmHg, white bar) or arterial (100 mmHg, black bars)
pressure profiles for the indicated time relative to the unperfused controls of the same veins, respectively.
10 mmHg 1 day (n = 5), 10 mmHg 3 days (n = 3), 10 mmHg 5 days (n = 4), 100 mmHg 1 day (n = 3), 100
mmHg 3 days (n = 5), 100 mmHg 5 days (n = 4). The MMP-2/b-actin ratio in unperfused veins was
arbitrarily set to 1.
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Page 8 of 14vein is exposed to arterial hemodynamic conditions. Therefore, our system may repre-
sent a valuable and reasonable approach to identify molecular mechanism underlying
the early stages of bypass grafting. Several in vitro and in vivo studies have demon-
strated changes in graft morphology, viability, cellular density or gene expression
under arterial conditions [7,16,22,27,28]. Saucy et al. for instance used an ex vivo vein
support system to perfuse HSVGs with arterial conditions regarding shear stress, flow
rate and pressure during a period of 7 and 14 days. They found significant IH and a
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Figure 4 Zymographic analysis of MMP-2 activity. A Representative results are shown for HSVGs
perfused with venous or arterial pressure. Controls represent MMP-2 activity of unperfused tissue taken
from the same vein (n = 5 for each condition). B Quantitative analysis of MMP-2 gelatinolytic activity. The
activity in unperfused veins was arbitrarily set to 1.
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Page 9 of 14marked increase in plasminogen activator inhibitor 1 (PAI-1) expression in the human
veins after 7 and 14 days of perfusion [29]. A mathematical model of early vein graft
IH induced by shear stress and based on experimental data with bilateral rabbit carotid
vein grafts describes the general behavior of the remodeling process [23]. The group of
Porter et al. demonstrated that arterial shear stress inhibits the development of IH in
cultured vein pieces [30]. Previous studies have shown that SMC proliferation and
migration depend on the activity of matrix-degrading enzymes. In fact, MMP-2 is an
enzyme which is directly involved in vascular remodeling [14] and rodent animal mod-
els confirm that MMP-2 levels are increased under hypertensive conditions [20,21].
Within three days of perfusion under arterial pressure conditions in our perfusion
system the expression of MMP-2 increased more than nine-fold and reached an even
higher value after five days, similar to the activation of PAI-1 [31]. Our data are further
supported by other reports which shows an increased de novo synthesis of MMP-2 in
HSVGs perfused with artertial conditions [22] or in animal models who underwent
vein grafting [8,16]. Berceli et al used a rabbit model with bilateral common carotid
interposition vein grafting. They could show that accelerated IH resulting from reduc-
tion in wall shear stress was associated with an increase in MMP-2, mainly in an active
form [16]. Our zymographic analyses are in accordance with their results and those of
Patterson et al. [17], as we found strongly increased gelatinolytic activities in veins
after perfusion with arterial pressure profiles particularly of the active form of MMP-2.
As we compared HSVGs under venous or arterial pressure conditions, the elevation of
MMP-2 can be attributed strongly to the arterial pressure profile. Both, gene and pro-
tein expression were significantly increased after perfusion with an arterial hemody-
namic profile compared to venous conditions although all HSVGs had the same
mechanical injuries after harvesting and mounting in the ex vivo perfusion system.
Thus, the results of our perfusion system perfectly reflect the in vivo situation suggest-
ing that genes which are involved in vascular remodeling are activated by arterial pres-
sure. Therefore, our system can be used to analyze molecular parameters involved
in such events in detail under standardized, tightly controlled and reproducible
conditions.
An important advantage of our system is the possibility to mount vessels of variable
length and diameter. The sliding unit allow sav e r yf l e x i b l ea d j u s t m e n tt og u a r a n t e e
that the vessel maintains its natural length and tension throughout the experiment.
Our main focus was to setup an experimental system, which is suitable to reliably ana-
lyze molecular parameters as a function of altered pressure and flow conditions. There-
fore, the most important point was to control the pressure conditions very stringently
and also to keep them very stable. In pilot experiments we experienced a continuously
decreasing pressure in the circuit, despite any leakage. Knowing that pressure affects
gene expression such a behavior would be fatal for a desired molecular readout. With
regard to this a unique feature of our perfusion system is the regulation of the mean
pressure in the circuit by a computer controlled syringe pump. Decreasing pressure
due to diffusion processes through out the silicone tubing [32] or relaxation of the ves-
sel can be compensated automatically. Long time trials can be performed due to this
amendment enabling an objectively constant mean pressure. In addition, up to four
grafts can be perfused simultaneously within one circuit. Using MTT conversion we
were able to confirm that HSVGs, which were perfused with a low-pressure profile in
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Page 10 of 14our system, remained viable for up to two weeks. This is in good agreement with other
reports which have estimated the integrity of the vessels by histological or immunohis-
tochemical methods [28,31,33]. Switching the conditions to an arterial pressure profile
leads to a visible reduction of the MTT staining beyond five days of perfusion. These
findings are similar to those of Miyakawa et al. who detected diminished cell viability
in vein segments after perfusion with arterial conditions for four days [28]. They con-
firmed their results by hematoxylin staining which also reveals a reduction of nuclear
s t a i n i n go nd a yf o u r[ 2 8 ] .G u s i ce ta l .c o u l de v e ns h o wad r a m a t i ci n c r e a s ei nc e l l
death index in all layers of the graft after one week [7]. We have also performed
experiments in which HSVGs were perfused with pathologically elevated pressure (200
mmHg). However, under these conditions the grafts rapidly degenerated and after two
days no MTT conversion was detected any more (data not shown). Our study, like
others, is limited by the inability to perfuse the ex vivo system with autologous blood
lacking blood cells, platelets, plasma, blood-surface interaction and the multitude of
inflammatory and coagulation mediators playing an important role in the pathophysiol-
ogy of IH development. However, because of technical reasons, we were not able to
perfuse veins with blood by using a roller pump for perfusion to achieve a pulsatile
flow. Platelets would be inevitably activated and blood cells destroyed during passage
through the pump. Hemolysis could be avoided or highly reduced by using a centrifu-
gal pump instead, which in turn produces a nonpulsatile flow. Inclusion of blood
would provide exposure of the vein to a more physiological state, but may also con-
found the results with numerous other variables. Another limitation is the time-
restricted viability of grafts in the ex vivo perfusion system which would not be pro-
longed by blood perfusion due to the accumulated metabolic waste products and
inflammatory reactions. Despite these limitations, the findings of the current study
highlight important potential in our understanding of the healing and adaptation of
veins transplanted to the arterial environment. From the beginning of the development
we tried to keep the total volume of the circuit relatively small. At present it comprises
approximately 20 ml which is substantially lower compared to other systems which use
volumes up to 500 ml [30,34]. If necessary the circuit can be scaled down even further
to a volume of approximately 10 ml. Exogenous substances can be added in a defined
concentration with a reasonable and affordable consumption of material, even during
long-term experiments with repeated changes of medium and substances. One concei-
vable scenario is the induction of an inflammatory reaction in the vein followed by the
addition of recently developed anti-inflammatory drugs [35,36]. Another most obvious
application is the use of small molecules which have shown their anti-angiogenic
potential in vitro [37]. Our system might unveil novel aspects about the activity of
such molecules as the affected endothelial cells are located in their natural environ-
ment and maintain their physiological interactions with other cell types.
Conclusions
In summary, we have developed a novel ex vivo perfusion system which maintains
human veins viable for up to two weeks under a low pressure profile. The setup guar-
antees a tightly controlled and stable perfusion rate and the system proved to be suita-
ble to record alterations in gene and protein expression induced by different perfusion
profiles. Further advantages of our system are a total flexibility concerning the size of
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tion of defined amounts of exogenous substances into the circuit. Our ex vivo perfu-
sion system and its applications may, therefore, help to improve the long-term patency
of human bypass grafts.
Additional material
Additional File 1: Figure S1. Histological analysis of a representative formalin fixed and paraffin-embedded HSVG
after perfusion with different pressure profiles and hematoxylin/eosin staining. The control represents the
unperfused vessel. The other parts of the vein were perfused with physiological venous (10 mmHg) or arterial
pressure (100 mmHg) for the time indicated.
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